254 related articles for article (PubMed ID: 31369299)
1. Health economic evaluation of current vaccination strategies and new vaccines against tuberculosis: a systematic review.
Machlaurin A; Pol SV; Setiawan D; van der Werf TS; Postma MJ
Expert Rev Vaccines; 2019 Sep; 18(9):897-911. PubMed ID: 31369299
[No Abstract] [Full Text] [Related]
2. Economic Evaluation of Selective Neonatal Bacillus Calmette-Guérin Vaccination of High-risk Infants in Ireland.
Teljeur C; Moran PS; Harrington P; Butler K; Corcoran B; O'Donnell J; Usher C; O'Flanagan D; Connolly K; Ryan M
Pediatr Infect Dis J; 2018 Aug; 37(8):759-767. PubMed ID: 29432385
[TBL] [Abstract][Full Text] [Related]
3. Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting.
Fu H; Lin HH; Hallett TB; Arinaminpathy N
Vaccine; 2018 Sep; 36(39):5902-5909. PubMed ID: 30143270
[TBL] [Abstract][Full Text] [Related]
4. Is Bacillus Calmette-Guerin revaccination necessary for Japanese children?
Rahman M; Sekimoto M; Hira K; Koyama H; Imanaka Y; Fukui T
Prev Med; 2002 Jul; 35(1):70-7. PubMed ID: 12079443
[TBL] [Abstract][Full Text] [Related]
5. Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.
Dye C
J R Soc Interface; 2013 Oct; 10(87):20130365. PubMed ID: 23904584
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis.
Abubakar I; Pimpin L; Ariti C; Beynon R; Mangtani P; Sterne JA; Fine PE; Smith PG; Lipman M; Elliman D; Watson JM; Drumright LN; Whiting PF; Vynnycky E; Rodrigues LC
Health Technol Assess; 2013 Sep; 17(37):1-372, v-vi. PubMed ID: 24021245
[TBL] [Abstract][Full Text] [Related]
7. A review of the literature on the economics of vaccination against TB.
Tu HA; Vu HD; Rozenbaum MH; Woerdenbag HJ; Postma MJ
Expert Rev Vaccines; 2012 Mar; 11(3):303-17. PubMed ID: 22380823
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of universal BCG vaccination of Japanese infants.
Rahman M; Sekimoto M; Takamatsu I; Hira K; Shimbo T; Toyoshima K; Fukui T
Int J Epidemiol; 2001 Apr; 30(2):380-5. PubMed ID: 11369746
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland.
Hersh AL; Tala-Heikkilä M; Tala E; Tosteson AN; Fordham von Reyn C
Int J Tuberc Lung Dis; 2003 Jan; 7(1):22-9. PubMed ID: 12701831
[TBL] [Abstract][Full Text] [Related]
10. BCG vaccination strategies against tuberculosis: updates and perspectives.
Qu M; Zhou X; Li H
Hum Vaccin Immunother; 2021 Dec; 17(12):5284-5295. PubMed ID: 34856853
[TBL] [Abstract][Full Text] [Related]
11. Targeted BCG vaccination against severe tuberculosis in low-prevalence settings: epidemiologic and economic assessment.
Altes HK; Dijkstra F; Lugnèr A; Cobelens F; Wallinga J
Epidemiology; 2009 Jul; 20(4):562-8. PubMed ID: 19295437
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui.
Lanckriet C; Lévy-Bruhl D; Bingono E; Siopathis RM; Guérin N
Int J Epidemiol; 1995 Oct; 24(5):1042-9. PubMed ID: 8557438
[TBL] [Abstract][Full Text] [Related]
13. Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.
Xing Z; Charters TJ
Expert Rev Vaccines; 2007 Aug; 6(4):539-46. PubMed ID: 17669008
[TBL] [Abstract][Full Text] [Related]
14. New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
BMC Med; 2023 Aug; 21(1):288. PubMed ID: 37542319
[TBL] [Abstract][Full Text] [Related]
15. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices.
MMWR Recomm Rep; 1996 Apr; 45(RR-4):1-18. PubMed ID: 8602127
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of bacille Calmette-Guérin immunisation programs in Australia.
Khandaker G; Beard FH; Dey A; Coulter C; Hendry AJ; Macartney KK
Commun Dis Intell Q Rep; 2017 Mar; 41(1):E33-E48. PubMed ID: 28385137
[TBL] [Abstract][Full Text] [Related]
17. [BCG vaccines for the prevention of tuberculosis in the world].
Hashimoto T
Kekkaku; 1997 Nov; 72(11):629-37. PubMed ID: 9423301
[TBL] [Abstract][Full Text] [Related]
18. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
Front Immunol; 2018; 9():2371. PubMed ID: 30386336
[TBL] [Abstract][Full Text] [Related]
19. Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis.
Mahasha PW; Ndwandwe DE; Mavundza EJ; Shey M; Wiysonge CS
BMJ Open; 2019 Oct; 9(10):e027033. PubMed ID: 31619416
[TBL] [Abstract][Full Text] [Related]
20. Pros and cons of BCG vaccination in countries with low incidence of tuberculosis.
Tala EO; Tala-Heikkilä MM
Infect Control Hosp Epidemiol; 1994 Jul; 15(7):497-9. PubMed ID: 7963444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
